Research & publications
Original research is at the heart of what we do. For more than 60 years, our experts have published across a wide range of topics from the fundamentals of health economics itself to the challenges facing health care in the UK and internationally.
The latest research and publications
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
The case for adopting a broader perspective on value in Health Technology Assessment
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
The case for adopting a broader perspective on value in Health Technology Assessment
In this Whitepaper, we describe different perspectives that can be adopted in…
Novel devices: optimising drug delivery in multiple myeloma
Biologics: Driving innovation in the treatment of multiple myeloma Biological…
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by…
Capturing the lived experiences of informal care in acute leukemia
Providing informal care to someone living with acute leukemia imposes a severe…
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive…
Achieving Accelerated Patient Access to Cancer Care in Europe
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE)…
Patient preferences for treatment in relapsed/refractory acute leukemia
When acute leukemia relapses, treatment decisions can be complex. Patients may…
The value of cell and gene therapies to the UK economy
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to…
The broader economic benefits of COVID-19 vaccination
Extending COVID-19 vaccination eligibility to working-age adults could nearly…
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related…